| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 272 | 2024 | 5317 | 15.100 |
Why?
|
| Skin Neoplasms | 197 | 2024 | 4654 | 11.440 |
Why?
|
| Sentinel Lymph Node Biopsy | 73 | 2023 | 1415 | 6.500 |
Why?
|
| Lymph Node Excision | 49 | 2023 | 1959 | 2.850 |
Why?
|
| Neoplasm Staging | 100 | 2024 | 13658 | 2.630 |
Why?
|
| Lymphatic Metastasis | 80 | 2022 | 4844 | 2.460 |
Why?
|
| Lymph Nodes | 44 | 2023 | 2967 | 1.990 |
Why?
|
| Sentinel Lymph Node | 6 | 2021 | 216 | 1.780 |
Why?
|
| Humans | 301 | 2024 | 261506 | 1.120 |
Why?
|
| Prognosis | 78 | 2024 | 21713 | 1.060 |
Why?
|
| Medical Oncology | 7 | 2023 | 1423 | 1.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 16 | 2022 | 1283 | 0.970 |
Why?
|
| Practice Guidelines as Topic | 14 | 2021 | 2403 | 0.950 |
Why?
|
| Lymphangiogenesis | 3 | 2012 | 46 | 0.880 |
Why?
|
| Mitotic Index | 6 | 2023 | 162 | 0.850 |
Why?
|
| Sunbathing | 2 | 2016 | 10 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 31 | 2022 | 10035 | 0.670 |
Why?
|
| Biomarkers, Tumor | 24 | 2021 | 10331 | 0.640 |
Why?
|
| United States | 32 | 2024 | 15433 | 0.630 |
Why?
|
| Sunburn | 3 | 2016 | 35 | 0.630 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 95 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 4 | 2023 | 1350 | 0.610 |
Why?
|
| Primary Prevention | 2 | 2018 | 255 | 0.600 |
Why?
|
| Middle Aged | 127 | 2023 | 86204 | 0.600 |
Why?
|
| Risk Assessment | 16 | 2020 | 6869 | 0.600 |
Why?
|
| Melanoma, Experimental | 5 | 2021 | 368 | 0.590 |
Why?
|
| Male | 141 | 2023 | 123000 | 0.580 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 383 | 0.580 |
Why?
|
| Interferon-alpha | 6 | 2016 | 889 | 0.550 |
Why?
|
| Female | 143 | 2022 | 141928 | 0.550 |
Why?
|
| CTLA-4 Antigen | 8 | 2023 | 657 | 0.540 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 7 | 2020 | 992 | 0.540 |
Why?
|
| Fellowships and Scholarships | 3 | 2019 | 390 | 0.520 |
Why?
|
| Tanning | 1 | 2014 | 2 | 0.520 |
Why?
|
| Adult | 99 | 2024 | 77950 | 0.510 |
Why?
|
| Sunscreening Agents | 2 | 2016 | 33 | 0.510 |
Why?
|
| Drug Labeling | 1 | 2014 | 29 | 0.510 |
Why?
|
| Ultraviolet Rays | 7 | 2023 | 575 | 0.490 |
Why?
|
| Surgical Oncology | 4 | 2020 | 190 | 0.480 |
Why?
|
| Databases, Factual | 14 | 2019 | 2218 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 4975 | 0.480 |
Why?
|
| Aged | 90 | 2021 | 70117 | 0.470 |
Why?
|
| Tumor Burden | 7 | 2019 | 1987 | 0.440 |
Why?
|
| Lymphedema | 7 | 2017 | 239 | 0.430 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2012 | 5 | 0.430 |
Why?
|
| Immunotherapy | 17 | 2023 | 3341 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2023 | 907 | 0.430 |
Why?
|
| Neoplasm Metastasis | 18 | 2020 | 5112 | 0.420 |
Why?
|
| Aged, 80 and over | 55 | 2020 | 29902 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 4549 | 0.420 |
Why?
|
| Molecular Targeted Therapy | 6 | 2022 | 2330 | 0.420 |
Why?
|
| Conjunctival Neoplasms | 3 | 2003 | 120 | 0.410 |
Why?
|
| Health Policy | 1 | 2014 | 291 | 0.410 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2021 | 1048 | 0.410 |
Why?
|
| Societies, Medical | 5 | 2017 | 1335 | 0.410 |
Why?
|
| Endothelial Cells | 5 | 2015 | 1048 | 0.410 |
Why?
|
| Mutation | 22 | 2021 | 15179 | 0.410 |
Why?
|
| Survival Analysis | 25 | 2022 | 9180 | 0.400 |
Why?
|
| Lysophospholipids | 1 | 2012 | 147 | 0.400 |
Why?
|
| SEER Program | 5 | 2018 | 1000 | 0.400 |
Why?
|
| Interleukin-8 | 2 | 2012 | 519 | 0.390 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 598 | 0.380 |
Why?
|
| Disease-Free Survival | 28 | 2022 | 10001 | 0.370 |
Why?
|
| Carcinoma, Merkel Cell | 4 | 2016 | 155 | 0.370 |
Why?
|
| Drug Eruptions | 1 | 2012 | 256 | 0.360 |
Why?
|
| Neoplasms | 12 | 2023 | 15193 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 5 | 2020 | 3976 | 0.340 |
Why?
|
| Biopsy | 16 | 2019 | 3443 | 0.340 |
Why?
|
| Adolescent | 42 | 2024 | 31252 | 0.340 |
Why?
|
| Neovascularization, Pathologic | 6 | 2011 | 1547 | 0.340 |
Why?
|
| Risk Factors | 30 | 2023 | 17523 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2020 | 5539 | 0.330 |
Why?
|
| Radionuclide Imaging | 8 | 2011 | 660 | 0.330 |
Why?
|
| Positron-Emission Tomography | 6 | 2014 | 2173 | 0.330 |
Why?
|
| Predictive Value of Tests | 15 | 2019 | 4892 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 527 | 0.320 |
Why?
|
| Watchful Waiting | 3 | 2021 | 289 | 0.320 |
Why?
|
| Nevus | 4 | 2021 | 107 | 0.320 |
Why?
|
| Retrospective Studies | 45 | 2023 | 37905 | 0.320 |
Why?
|
| Multivariate Analysis | 18 | 2020 | 4298 | 0.310 |
Why?
|
| Survival Rate | 24 | 2022 | 12221 | 0.300 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 226 | 0.300 |
Why?
|
| Specialties, Surgical | 1 | 2009 | 137 | 0.300 |
Why?
|
| Immunohistochemistry | 12 | 2020 | 7548 | 0.290 |
Why?
|
| International Cooperation | 1 | 2008 | 323 | 0.290 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 671 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 8873 | 0.290 |
Why?
|
| Nomograms | 2 | 2020 | 313 | 0.290 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 5 | 2003 | 115 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.290 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 47 | 0.280 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 251 | 0.280 |
Why?
|
| Lymphatic Vessels | 3 | 2015 | 143 | 0.280 |
Why?
|
| Endothelium, Lymphatic | 2 | 2015 | 14 | 0.270 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 2283 | 0.270 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2024 | 192 | 0.270 |
Why?
|
| Genome-Wide Association Study | 6 | 2020 | 2265 | 0.270 |
Why?
|
| Proportional Hazards Models | 17 | 2024 | 4988 | 0.260 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 5159 | 0.260 |
Why?
|
| Tomography, Emission-Computed | 1 | 2006 | 310 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 2483 | 0.260 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 66 | 0.260 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 29 | 0.260 |
Why?
|
| Case-Control Studies | 20 | 2023 | 6100 | 0.260 |
Why?
|
| Genes, ras | 3 | 2013 | 667 | 0.250 |
Why?
|
| Polymorphism, Genetic | 6 | 2008 | 1450 | 0.250 |
Why?
|
| Body Mass Index | 5 | 2023 | 2203 | 0.250 |
Why?
|
| Precision Medicine | 3 | 2017 | 1154 | 0.240 |
Why?
|
| Internship and Residency | 3 | 2020 | 1375 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2003 | 13 | 0.240 |
Why?
|
| Uveal Neoplasms | 2 | 2017 | 176 | 0.240 |
Why?
|
| Radiopharmaceuticals | 4 | 2006 | 1301 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 1248 | 0.230 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 14889 | 0.230 |
Why?
|
| Survivors | 3 | 2016 | 1031 | 0.230 |
Why?
|
| Dermatologic Surgical Procedures | 4 | 2019 | 106 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 371 | 0.220 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 1519 | 0.220 |
Why?
|
| Evidence-Based Medicine | 5 | 2016 | 1085 | 0.220 |
Why?
|
| Child | 23 | 2022 | 29154 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 12 | 2018 | 3981 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2023 | 489 | 0.220 |
Why?
|
| Guideline Adherence | 3 | 2015 | 636 | 0.210 |
Why?
|
| Skin Ulcer | 4 | 2013 | 77 | 0.210 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 411 | 0.210 |
Why?
|
| Biomedical Research | 5 | 2021 | 806 | 0.210 |
Why?
|
| Cohort Studies | 16 | 2021 | 9244 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| DNA-Binding Proteins | 8 | 2016 | 4821 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Patient Selection | 4 | 2020 | 2055 | 0.210 |
Why?
|
| Italy | 5 | 2023 | 236 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 502 | 0.200 |
Why?
|
| Incidence | 9 | 2020 | 5673 | 0.200 |
Why?
|
| Australia | 5 | 2021 | 225 | 0.200 |
Why?
|
| Young Adult | 24 | 2020 | 21445 | 0.200 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2012 | 58 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 112 | 0.200 |
Why?
|
| Transcription Factor AP-2 | 4 | 2006 | 79 | 0.200 |
Why?
|
| Disease Progression | 12 | 2023 | 6682 | 0.200 |
Why?
|
| Dermatology | 2 | 2019 | 70 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 123 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 1249 | 0.190 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 1162 | 0.190 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 6009 | 0.190 |
Why?
|
| Skin | 4 | 2018 | 1259 | 0.190 |
Why?
|
| Genes, Dominant | 1 | 2001 | 331 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 1226 | 0.190 |
Why?
|
| Mice | 24 | 2022 | 34495 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 126 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 299 | 0.180 |
Why?
|
| Ipilimumab | 3 | 2023 | 710 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2019 | 3890 | 0.180 |
Why?
|
| Policy | 1 | 2020 | 49 | 0.180 |
Why?
|
| Antineoplastic Agents | 13 | 2016 | 14289 | 0.180 |
Why?
|
| Frozen Sections | 2 | 2014 | 105 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.180 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 33 | 0.180 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 4849 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 1303 | 0.180 |
Why?
|
| DNA Repair | 5 | 2013 | 1872 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 986 | 0.180 |
Why?
|
| Internationality | 2 | 2011 | 208 | 0.180 |
Why?
|
| Health Promotion | 2 | 2021 | 502 | 0.180 |
Why?
|
| Sunlight | 5 | 2018 | 79 | 0.170 |
Why?
|
| B7 Antigens | 1 | 2020 | 84 | 0.170 |
Why?
|
| Dermoscopy | 1 | 2019 | 14 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 87 | 0.170 |
Why?
|
| Interleukin-6 | 3 | 2021 | 1038 | 0.170 |
Why?
|
| Models, Theoretical | 2 | 2018 | 785 | 0.170 |
Why?
|
| Lymphoscintigraphy | 1 | 1999 | 35 | 0.170 |
Why?
|
| Prospective Studies | 18 | 2023 | 12873 | 0.170 |
Why?
|
| Pathologists | 1 | 2019 | 91 | 0.170 |
Why?
|
| Smartphone | 1 | 2019 | 34 | 0.170 |
Why?
|
| Neck | 2 | 2020 | 383 | 0.170 |
Why?
|
| Mice, Nude | 11 | 2019 | 4307 | 0.170 |
Why?
|
| Eligibility Determination | 1 | 2019 | 77 | 0.170 |
Why?
|
| Signal Transduction | 8 | 2018 | 11965 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Cell Division | 1 | 2023 | 2489 | 0.170 |
Why?
|
| Up-Regulation | 6 | 2020 | 2450 | 0.170 |
Why?
|
| Margins of Excision | 1 | 2020 | 285 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2018 | 1171 | 0.160 |
Why?
|
| Treatment Outcome | 25 | 2020 | 32848 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 497 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 299 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 135 | 0.160 |
Why?
|
| Rosaniline Dyes | 4 | 2004 | 108 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 529 | 0.160 |
Why?
|
| Lung Neoplasms | 6 | 2022 | 11538 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2019 | 119 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 374 | 0.160 |
Why?
|
| Neuregulin-1 | 1 | 2018 | 83 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Animals | 29 | 2022 | 59536 | 0.160 |
Why?
|
| Medical Records | 1 | 2019 | 415 | 0.160 |
Why?
|
| Radiation-Protective Agents | 1 | 2018 | 128 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 6942 | 0.160 |
Why?
|
| Receptor, ErbB-3 | 1 | 2018 | 122 | 0.160 |
Why?
|
| Europe | 4 | 2024 | 649 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 314 | 0.150 |
Why?
|
| DNA Primers | 5 | 2013 | 1399 | 0.150 |
Why?
|
| Ulcer | 1 | 2018 | 78 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 160 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 250 | 0.150 |
Why?
|
| Lymphatic Irradiation | 3 | 2008 | 133 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 7 | 2022 | 4367 | 0.150 |
Why?
|
| Pathology | 1 | 2018 | 101 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 6207 | 0.150 |
Why?
|
| Mentoring | 1 | 2019 | 87 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 15862 | 0.150 |
Why?
|
| Confidence Intervals | 6 | 2019 | 756 | 0.150 |
Why?
|
| Beauty Culture | 1 | 2016 | 4 | 0.150 |
Why?
|
| Odds Ratio | 9 | 2019 | 2316 | 0.150 |
Why?
|
| Genome, Human | 3 | 2018 | 1869 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 1998 | 250 | 0.140 |
Why?
|
| Receptors, Calcitriol | 2 | 2008 | 134 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 175 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 598 | 0.140 |
Why?
|
| Clinical Trials as Topic | 7 | 2019 | 3719 | 0.140 |
Why?
|
| DNA Methylation | 3 | 2022 | 2669 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 878 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2018 | 1763 | 0.140 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 3869 | 0.140 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2016 | 41 | 0.140 |
Why?
|
| Mitosis | 3 | 2013 | 615 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 610 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 329 | 0.140 |
Why?
|
| American Cancer Society | 1 | 2016 | 31 | 0.140 |
Why?
|
| Melanocytes | 3 | 2021 | 219 | 0.140 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2016 | 47 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.140 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 388 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2015 | 479 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2018 | 314 | 0.140 |
Why?
|
| Minors | 1 | 2015 | 8 | 0.130 |
Why?
|
| Mastectomy | 3 | 2015 | 1534 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 482 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2015 | 16 | 0.130 |
Why?
|
| Inflammation | 2 | 2019 | 2522 | 0.130 |
Why?
|
| Texas | 9 | 2020 | 6311 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 182 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 348 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 3552 | 0.130 |
Why?
|
| Nuclear Proteins | 6 | 2014 | 3343 | 0.130 |
Why?
|
| Mutagens | 1 | 2016 | 187 | 0.130 |
Why?
|
| Inosine | 1 | 2015 | 39 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 778 | 0.130 |
Why?
|
| Cytokines | 3 | 2019 | 2809 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 607 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 3251 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2016 | 2927 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 7551 | 0.130 |
Why?
|
| Cell Line, Tumor | 11 | 2021 | 14551 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 236 | 0.120 |
Why?
|
| Antibodies | 2 | 2015 | 838 | 0.120 |
Why?
|
| Metalloproteins | 1 | 2014 | 26 | 0.120 |
Why?
|
| RNA Editing | 1 | 2015 | 92 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 612 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2019 | 929 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2054 | 0.120 |
Why?
|
| Combined Modality Therapy | 6 | 2023 | 8865 | 0.120 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 3639 | 0.120 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 309 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 5178 | 0.120 |
Why?
|
| Leptin | 1 | 2016 | 295 | 0.120 |
Why?
|
| Freezing | 1 | 2014 | 59 | 0.120 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 6089 | 0.120 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 93 | 0.120 |
Why?
|
| Integrin alpha4 | 2 | 2011 | 25 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 19 | 0.120 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 2216 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1294 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 261 | 0.120 |
Why?
|
| Ribosomal Proteins | 1 | 2014 | 118 | 0.120 |
Why?
|
| Transcription Factors | 5 | 2015 | 5270 | 0.120 |
Why?
|
| Time Factors | 8 | 2019 | 12926 | 0.120 |
Why?
|
| Thioredoxins | 1 | 2013 | 50 | 0.110 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 690 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 332 | 0.110 |
Why?
|
| Obesity | 4 | 2023 | 2884 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1081 | 0.110 |
Why?
|
| Algorithms | 4 | 2019 | 3890 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 288 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 706 | 0.110 |
Why?
|
| Genotype | 8 | 2020 | 4109 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 4744 | 0.110 |
Why?
|
| Logistic Models | 5 | 2019 | 3441 | 0.110 |
Why?
|
| Adenosine | 1 | 2015 | 289 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2012 | 1121 | 0.110 |
Why?
|
| Registries | 2 | 2017 | 2170 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 137 | 0.110 |
Why?
|
| MicroRNAs | 3 | 2022 | 2947 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 1265 | 0.110 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1516 | 0.100 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2012 | 80 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 999 | 0.100 |
Why?
|
| Surgeons | 1 | 2019 | 519 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 552 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1371 | 0.100 |
Why?
|
| Cell Movement | 3 | 2012 | 2466 | 0.100 |
Why?
|
| Base Sequence | 6 | 2015 | 4917 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2016 | 261 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1331 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 984 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 334 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 803 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 5687 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 5395 | 0.100 |
Why?
|
| Chi-Square Distribution | 5 | 2012 | 1323 | 0.100 |
Why?
|
| Age Factors | 6 | 2016 | 5377 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2016 | 2231 | 0.100 |
Why?
|
| Phosphotransferases | 1 | 2011 | 84 | 0.100 |
Why?
|
| Exons | 2 | 2011 | 1328 | 0.100 |
Why?
|
| Metalloproteases | 1 | 2010 | 24 | 0.100 |
Why?
|
| Mutagenesis | 1 | 2012 | 483 | 0.100 |
Why?
|
| Mammaplasty | 1 | 1998 | 780 | 0.100 |
Why?
|
| Population Surveillance | 2 | 2012 | 627 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 217 | 0.090 |
Why?
|
| Medicine | 1 | 2012 | 137 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 764 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 585 | 0.090 |
Why?
|
| Inguinal Canal | 1 | 2010 | 60 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2010 | 134 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 4938 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 543 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 1990 | 172 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2006 | 2086 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2012 | 5637 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2013 | 549 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 129 | 0.090 |
Why?
|
| Quality of Life | 4 | 2015 | 4532 | 0.090 |
Why?
|
| Caspase 10 | 1 | 2008 | 21 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2011 | 481 | 0.090 |
Why?
|
| Biomarkers | 2 | 2021 | 5047 | 0.090 |
Why?
|
| Apoptosis | 4 | 2013 | 7591 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2012 | 842 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 2594 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 6 | 2006 | 2314 | 0.080 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 884 | 0.080 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2021 | 149 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2017 | 5542 | 0.080 |
Why?
|
| Consensus | 3 | 2020 | 978 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2008 | 45 | 0.080 |
Why?
|
| Risk | 4 | 2016 | 1972 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 2291 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 3101 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 145 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 259 | 0.080 |
Why?
|
| Seroma | 1 | 2008 | 79 | 0.080 |
Why?
|
| Haplotypes | 4 | 2013 | 856 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2020 | 760 | 0.080 |
Why?
|
| Data Collection | 1 | 2011 | 620 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2014 | 1090 | 0.080 |
Why?
|
| Pandemics | 3 | 2024 | 1559 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 488 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 528 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 3 | 2015 | 336 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 1073 | 0.080 |
Why?
|
| Intraoperative Care | 2 | 2007 | 259 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1258 | 0.080 |
Why?
|
| Intraoperative Period | 3 | 2005 | 246 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 139 | 0.080 |
Why?
|
| Radiography | 3 | 2008 | 1904 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2007 | 53 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 447 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2015 | 639 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1016 | 0.070 |
Why?
|
| Clone Cells | 2 | 2020 | 555 | 0.070 |
Why?
|
| Neurofibromatoses | 1 | 2006 | 17 | 0.070 |
Why?
|
| Mass Screening | 1 | 2015 | 1509 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 15694 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1493 | 0.070 |
Why?
|
| CpG Islands | 1 | 2009 | 633 | 0.070 |
Why?
|
| False Negative Reactions | 3 | 2009 | 275 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 272 | 0.070 |
Why?
|
| Receptor, PAR-1 | 1 | 2006 | 33 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2006 | 256 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 622 | 0.070 |
Why?
|
| Back | 1 | 2006 | 45 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2012 | 1529 | 0.070 |
Why?
|
| Lymphatic System | 1 | 2006 | 64 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| Adrenalectomy | 2 | 2023 | 188 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 450 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2008 | 649 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 66 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2015 | 798 | 0.070 |
Why?
|
| Models, Biological | 2 | 2012 | 3254 | 0.070 |
Why?
|
| Chromatids | 1 | 2005 | 78 | 0.070 |
Why?
|
| Interferons | 1 | 2007 | 291 | 0.070 |
Why?
|
| Lipoprotein Lipase | 1 | 1985 | 52 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2011 | 1442 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2006 | 355 | 0.070 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.070 |
Why?
|
| Histones | 1 | 2013 | 1466 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2017 | 1823 | 0.070 |
Why?
|
| Galectin 3 | 1 | 2006 | 138 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 2979 | 0.070 |
Why?
|
| Extremities | 2 | 2006 | 303 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2013 | 7226 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2012 | 1549 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2001 | 1506 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1618 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 1533 | 0.060 |
Why?
|
| Exome | 3 | 2016 | 1239 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 324 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2006 | 297 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2008 | 874 | 0.060 |
Why?
|
| New York | 1 | 2023 | 104 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2011 | 2358 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 247 | 0.060 |
Why?
|
| Sweden | 1 | 2003 | 70 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2007 | 1529 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 171 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 259 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.060 |
Why?
|
| Transfection | 3 | 2008 | 2944 | 0.060 |
Why?
|
| Axilla | 3 | 2015 | 902 | 0.050 |
Why?
|
| Epidermis | 1 | 2003 | 188 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 271 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2023 | 122 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 257 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2017 | 1863 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2011 | 1163 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2003 | 2292 | 0.050 |
Why?
|
| Transcriptome | 2 | 2022 | 1859 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 7702 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 4233 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 173 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 661 | 0.050 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2003 | 169 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2024 | 175 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 1183 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4053 | 0.050 |
Why?
|
| Diet | 2 | 2021 | 1440 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2013 | 3536 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2001 | 82 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2001 | 181 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 7789 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2001 | 157 | 0.050 |
Why?
|
| Eyelid Neoplasms | 1 | 2003 | 191 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 238 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 194 | 0.050 |
Why?
|
| Recurrence | 2 | 2000 | 4758 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2010 | 1062 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2021 | 136 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4757 | 0.050 |
Why?
|
| Ligands | 2 | 2015 | 995 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 75 | 0.050 |
Why?
|
| Culture Media | 1 | 2001 | 319 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2001 | 682 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2024 | 498 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2001 | 259 | 0.050 |
Why?
|
| Point Mutation | 3 | 2013 | 769 | 0.050 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 69 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2000 | 133 | 0.050 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 42 | 0.050 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.050 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 38 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 277 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 300 | 0.040 |
Why?
|
| Safety | 1 | 2001 | 465 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1152 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.040 |
Why?
|
| Arm | 2 | 2015 | 147 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2020 | 6150 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 233 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 34 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2101 | 0.040 |
Why?
|
| Membrane Proteins | 3 | 2015 | 2819 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2001 | 621 | 0.040 |
Why?
|
| Decision Making | 2 | 2016 | 1287 | 0.040 |
Why?
|
| Endonucleases | 2 | 2013 | 178 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 289 | 0.040 |
Why?
|
| Cell Communication | 2 | 2015 | 509 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 102 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2013 | 1489 | 0.040 |
Why?
|
| Thorax | 1 | 2000 | 213 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 437 | 0.040 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 1022 | 0.040 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 1998 | 55 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2018 | 54 | 0.040 |
Why?
|
| Students | 1 | 2021 | 324 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 770 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 1390 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2012 | 460 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 460 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 167 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 1144 | 0.040 |
Why?
|
| Sex Factors | 2 | 2016 | 2139 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 260 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 584 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Collagen | 1 | 2001 | 752 | 0.040 |
Why?
|
| Gelatinases | 1 | 1997 | 52 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Breast | 1 | 2004 | 1344 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 980 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 4557 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 253 | 0.040 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 88 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2003 | 620 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 95 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1998 | 116 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1008 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 905 | 0.040 |
Why?
|
| Chest Tubes | 1 | 1998 | 101 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2018 | 2508 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 130 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 702 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2018 | 241 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 419 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 170 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2013 | 938 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2008 | 2307 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 98 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2315 | 0.040 |
Why?
|
| Medicaid | 1 | 2019 | 279 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 6295 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2017 | 153 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2588 | 0.040 |
Why?
|
| Metagenome | 1 | 2017 | 176 | 0.040 |
Why?
|
| Sirolimus | 2 | 2013 | 814 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2018 | 299 | 0.040 |
Why?
|
| Mucin 5AC | 1 | 2016 | 75 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 243 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 1910 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 574 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 362 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 362 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 216 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 74 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1998 | 201 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 344 | 0.030 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 34 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 383 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.030 |
Why?
|
| Vermont | 1 | 2015 | 4 | 0.030 |
Why?
|
| Nevada | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 223 | 0.030 |
Why?
|
| Oregon | 1 | 2015 | 20 | 0.030 |
Why?
|
| Vinblastine | 2 | 2009 | 453 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 24 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 81 | 0.030 |
Why?
|
| State Government | 1 | 2015 | 33 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 651 | 0.030 |
Why?
|
| Drainage | 1 | 1998 | 416 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2015 | 34 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2015 | 52 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 237 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 94 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2015 | 53 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2015 | 72 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2015 | 60 | 0.030 |
Why?
|
| California | 1 | 2015 | 208 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 551 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 117 | 0.030 |
Why?
|
| DNA Damage | 1 | 2003 | 1954 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2015 | 88 | 0.030 |
Why?
|
| CD146 Antigen | 2 | 2008 | 57 | 0.030 |
Why?
|
| Alleles | 3 | 2006 | 2437 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 330 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2002 | 1202 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 4971 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2017 | 414 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Pelvis | 2 | 2007 | 362 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 194 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2006 | 652 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 305 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.030 |
Why?
|
| Hematocrit | 2 | 1992 | 142 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 1399 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 445 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 634 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2008 | 945 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1053 | 0.030 |
Why?
|
| Semiconductors | 1 | 2013 | 22 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 142 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1998 | 1385 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 672 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2013 | 70 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 298 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 476 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 169 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 694 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1992 | 684 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1313 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4804 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 3203 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 621 | 0.030 |
Why?
|
| Endotoxins | 1 | 1992 | 96 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2011 | 32 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 591 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2012 | 107 | 0.030 |
Why?
|
| Pigmentation | 1 | 2011 | 47 | 0.030 |
Why?
|
| Wound Infection | 1 | 1992 | 54 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 1546 | 0.030 |
Why?
|
| Burns | 1 | 1992 | 117 | 0.030 |
Why?
|
| Patient Care | 1 | 2012 | 149 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2015 | 850 | 0.020 |
Why?
|
| Peptide Library | 1 | 2011 | 158 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.020 |
Why?
|
| ADAMTS Proteins | 1 | 2010 | 15 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1992 | 196 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 392 | 0.020 |
Why?
|
| Turpentine | 1 | 1990 | 4 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2016 | 16273 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 276 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1990 | 93 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 159 | 0.020 |
Why?
|
| Corticosterone | 1 | 1990 | 119 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 1990 | 79 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 844 | 0.020 |
Why?
|
| Appetite | 1 | 1990 | 73 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 98 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 327 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 342 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 5437 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 1990 | 299 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3230 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3472 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1992 | 1538 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 121 | 0.020 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 997 | 0.020 |
Why?
|
| Cisplatin | 2 | 2009 | 2432 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 505 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2011 | 309 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2013 | 1113 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 324 | 0.020 |
Why?
|
| Body Weight | 2 | 1992 | 1293 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 461 | 0.020 |
Why?
|
| Peptides | 1 | 2015 | 1479 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 974 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 26 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13310 | 0.020 |
Why?
|
| Groin | 1 | 2008 | 74 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 51 | 0.020 |
Why?
|
| Suction | 1 | 2008 | 104 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 1099 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1945 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1694 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2007 | 105 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 1914 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1678 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 673 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3578 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1732 | 0.020 |
Why?
|
| Chromatin | 1 | 2013 | 942 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 130 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 1225 | 0.020 |
Why?
|
| Laser Scanning Cytometry | 1 | 2006 | 16 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 175 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2009 | 485 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2006 | 15 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2006 | 50 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 62 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 299 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 460 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Lipids | 1 | 1990 | 644 | 0.020 |
Why?
|
| Serine | 1 | 2007 | 388 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3569 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 864 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 854 | 0.020 |
Why?
|
| Nevus, Pigmented | 1 | 2006 | 104 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 1021 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1985 | 122 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 150 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 223 | 0.020 |
Why?
|
| Birds | 1 | 1985 | 92 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 170 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 246 | 0.020 |
Why?
|
| Social Support | 1 | 2008 | 560 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1985 | 629 | 0.020 |
Why?
|
| Purines | 1 | 2006 | 273 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 1489 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 1439 | 0.020 |
Why?
|
| Arginine | 1 | 2007 | 500 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 726 | 0.020 |
Why?
|
| Emotions | 1 | 2008 | 562 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2341 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1665 | 0.020 |
Why?
|
| Injections | 1 | 2004 | 285 | 0.010 |
Why?
|
| Interferon-beta | 1 | 2003 | 102 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8223 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 501 | 0.010 |
Why?
|
| Minority Groups | 1 | 2005 | 322 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 538 | 0.010 |
Why?
|
| Benzamides | 1 | 2008 | 1832 | 0.010 |
Why?
|
| Growth Substances | 1 | 2003 | 300 | 0.010 |
Why?
|
| Kinetics | 1 | 1985 | 2049 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2002 | 82 | 0.010 |
Why?
|
| Codon | 1 | 2002 | 241 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2001 | 61 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 698 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 557 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 717 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 2803 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 1546 | 0.010 |
Why?
|
| Brain | 1 | 2014 | 4113 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Edema | 1 | 2002 | 267 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1620 | 0.010 |
Why?
|
| Eating | 2 | 1992 | 421 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2006 | 1011 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.010 |
Why?
|
| Thoracostomy | 1 | 1998 | 43 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1997 | 118 | 0.010 |
Why?
|
| Retreatment | 1 | 1998 | 452 | 0.010 |
Why?
|
| Cyclins | 1 | 1998 | 456 | 0.010 |
Why?
|
| Arteries | 1 | 1998 | 274 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 462 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1998 | 1391 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 3842 | 0.010 |
Why?
|
| Oxygen | 1 | 1998 | 754 | 0.010 |
Why?
|
| Rats | 2 | 1992 | 6086 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 2422 | 0.010 |
Why?
|
| Acute-Phase Reaction | 1 | 1992 | 26 | 0.010 |
Why?
|
| Rats, Inbred BUF | 1 | 1992 | 26 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 410 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4320 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1992 | 205 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 1879 | 0.010 |
Why?
|
| Weight Gain | 1 | 1992 | 464 | 0.010 |
Why?
|
| Liver | 1 | 1992 | 2961 | 0.000 |
Why?
|